Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
about
Beta-blocker use and COPD mortality: a systematic review and meta-analysisHeart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiologySerial pulmonary function tests to diagnose COPD in chronic heart failureBeta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure StudyHeart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring deviceShort-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community.Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) - Polish population.Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure.Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTIONThe comorbidity conundrum: a focus on the role of noncardiovascular chronic conditions in the heart failure patient.Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services.Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.Chronic obstructive airway disease among patients hospitalized with acute heart failure; clinical characteristics, precipitating factors, management and outcome: Observational report from the Middle East.Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.COPD in heart failure: are there long-term implications following acute heart failure hospitalization?Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland.Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure.Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure.Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity.Prevalence of potential cardiac resynchronization therapy candidates and actual use of cardiac resynchronization therapy in patients hospitalized for heart failure.Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF.
P2860
Q27026866-C89B2D83-A7E0-4EFB-8117-DE55F939E7CFQ30483582-51A599D9-E087-4DDA-A913-6C5CDDC9EDECQ34253499-AC63551B-35E0-4A88-81B3-DA65217C51D5Q34575920-B4443E0A-BB03-4615-A2FD-1BEE0B8F2792Q35140970-BE47F021-B4B5-4752-8422-8B7907DC4A03Q35509920-64DB6AC9-2299-45DA-BBD6-06E9234C5975Q35852488-86CD104E-AA6D-4452-B465-F85E86A4BF7CQ35992082-A11E1377-98F6-4308-9842-DEE21A8E191FQ36042260-06929BE1-7A5F-4E29-B5B7-13577DB465E4Q36566759-F499695C-C779-42A6-B964-DD9B0621FC77Q37102979-AC2D90B1-4B07-448C-94BC-3AD3F0BB0530Q37146261-5BF76862-F245-463B-A409-A541AAE467EEQ37993441-1BAF08A3-3319-40F3-92EF-4DDA715FC640Q38119867-F44B4293-42B2-422C-B937-444FF2EAC72FQ38701409-A0CC48D8-0533-432E-9430-5BD55BC52928Q39200729-C179E737-3AC2-4355-9382-B9A18D02B4B2Q40789268-540659F6-2ACD-4B38-BC20-2646E53594FBQ43056249-57759173-495B-4121-A5BA-EA208452C7D7Q43113040-B17328F8-3A1F-41B4-96BD-5FDE0A1EFF00Q43792082-78ECE811-C576-4F95-8EF6-2736C5BD5202Q44616969-67004FEF-C3BF-4B29-BC91-14A18A662EDCQ45301370-739BA5F7-9A92-4A66-8896-72D181085434Q46738415-1C3C589C-5D73-4ABC-B5F2-05380B6FD7ADQ49170764-013AF0CC-681D-4CA6-97D4-C97664814DDFQ49832113-440BD413-648D-4D57-B69E-F2ACF88F3693Q50145168-8BFDE0FB-68D4-4915-A1A7-8576F49D089EQ51431426-94D7C239-0A44-4FF3-9D48-0D899ADEAD03
P2860
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clinical, neurohormonal, and i ...... Val-HeFT heart failure trial.
@ast
Clinical, neurohormonal, and i ...... Val-HeFT heart failure trial.
@en
type
label
Clinical, neurohormonal, and i ...... Val-HeFT heart failure trial.
@ast
Clinical, neurohormonal, and i ...... Val-HeFT heart failure trial.
@en
prefLabel
Clinical, neurohormonal, and i ...... Val-HeFT heart failure trial.
@ast
Clinical, neurohormonal, and i ...... Val-HeFT heart failure trial.
@en
P2093
P1476
Clinical, neurohormonal, and i ...... e Val-HeFT heart failure trial
@en
P2093
Aldo P Maggioni
Elisa Carretta
Gianni Tognoni
Jay N Cohn
Lidia Staszewsky
Maylene Wong
Roberto Latini
Serge Masson
Simona Barlera
Valsartan Heart Failure Trial Investigators
P304
P356
10.1016/J.CARDFAIL.2007.07.012
P577
2007-12-01T00:00:00Z